Proliverenol Supplementation for Non-Alcoholic Fatty Liver Disease (NAFLD)

Dexa Medica

Status and phase: Enrolling; Phase 2

Conditions: Non-Alcoholic Fatty Liver Disease (NAFLD)

Treatments: Drug: Proliverenol; Drug: Placebo caplets of Proliverenol

Study type: Interventional

Funder types: Industry

Identifiers

NCT06127225

CR.079/EQL/2021

Details and patient eligibility

About

This is a 4-arm, prospective, randomized, double-blind, double-dummy, and placebo-controlled clinical study comparing Proliverenol at a dose of 500 mg twice daily; Proliverenol at a dose of 1000 mg once daily; Proliverenol at a dose of 1000 mg twice daily; and Placebo two caplets daily for a 12-week course of therapy.

Proliverenol is a bioactive fraction derived from the dried fruit of Phaleria macrocarpa (Scheff.) Boerl (Thymelaeaceae). Proliverenol possesses a hepatoprotective activity via anti-inflammation, DNA repairing, and the antiapoptosis properties.

Full description

There will be 4 groups of treatment; each group will consist of 20 subjects with the treatment regimens for 12 weeks:

Treatment I : 1 caplet of Proliverenol 500 mg twice daily Treatment II : 2 caplets of Proliverenol 500 mg once daily Treatment III : 2 caplets of Proliverenol 500 mg twice daily Treatment IV : 2 caplets of Placebo daily

Study subjects will be asked to come to the clinic every 4-week interval throughout the study period.

Subjects will be evaluated for treatment efficacy at baseline and at interval of 4 weeks over the 12-week course of therapy. Throughout the 12-week therapy, subjects should record the product consumption and adverse event occurred during the study in the provided Patient's Diary.

The safety profile of study medication other than vital signs and adverse event will be measured at baseline and end of study.

Enrollment: 80 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Signed informed consent
2. Male or female subjects with age of 18 years or older at screening.
3. Diagnosed as NAFLD with liver ultrasonography (USG). Patients with bright liver appearance based on USG, will be followed by CAP examination. Steatosis is defined if CAP >263 dB/m
4. Presence of hepatic impairment, defined as any of serum ALT level > ULN
5. Able to take oral medication.

Exclusion criteria

1. Suspected positive COVID-19 based on clinical symptoms or SARS-COV-2 antigen test
2. Pregnancy and lactation period.
3. Suspected alcoholic liver disease
4. History of or presence of autoimmune liver diseases
5. Presence of Bilirubin level > 2x ULN
6. Uncontrolled Diabetes Mellitus with HbA1c ≥ 9.0%
7. History or presence of significant/advanced CV, metabolic, acute or chronic infectious diseases, including viral hepatitis (B and C), or malignancy.
8. Suspected cirrhosis as supported by biochemical profile (PLT count, albumin)
9. Presence of severe renal dysfunction
10. Current or regular use of drug-induced hepatotoxicity, such as: such as non-steroidal anti-inflammatory drugs (NSAIDs), antibiotics, anti-epileptic drugs (e.g. carbamazepines, phenytoin, barbiturates), or anti-tuberculous drugs other than the investigational product
11. Current or regular use of herbal medicines with hepato-protective properties
12. Known or suspected hypersensitivity to the trial product or related products

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

80 participants in 4 patient groups, including a placebo group

Treatment 1

Experimental group

Description:

1 caplet of Proliverenol 500 mg twice daily

Treatment:

Drug: Proliverenol

Treatment 2

Experimental group

Description:

2 caplets of Proliverenol 500 mg once daily

Treatment:

Drug: Proliverenol

Treatment 3

Experimental group

Description:

2 caplets of Proliverenol 500 mg twice daily

Treatment:

Drug: Proliverenol

Treatment 4

Placebo Comparator group

Description:

2 caplets of Placebo daily

Treatment:

Drug: Placebo caplets of Proliverenol